Lotronex(tm): therapy for diarrhea predominant irritable bowel syndrome.
McGahan
L
L
Canadian Coordinating Office for Health Technology Assessment. lyndam@ccohta.ca
D002170:Canada; D002243:Carbolines / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D003109:Colonic Diseases, Functional / Q000188:drug therapy* / Q000191:economics; D003967:Diarrhea / Q000188:drug therapy / Q000191:economics; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D008297:Male; D012702:Serotonin Antagonists / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D013673:Technology Assessment, Biomedical; D014481:United States
D002243:Carbolines; D005765:Gastrointestinal Agents; D012702:Serotonin Antagonists